The conventional management of patients with stage I seminoma of the testis is distinct from those with stage I non-seminomatous germ cell tumour (NSGCT). For seminoma this is by adjuvant retroperitoneal lymph node irradiation. This policy is highly successful, recurrences occur in less than 5% of patients (Hamilton et al., 1986; Zagars, 1991) and long-term morbidity is low (Horwich and Bell, 1994; Hamilton et al., 1987) . Surveillance has been investigated (Duchesne et al., 1990; Horwich et al., 1992; Oliver et al., 1994; Von der Maase et al., 1993; Thomas et al., 1989 ) but a number of clinical difficulties have become apparent: the relative indolent natural history of seminoma leading to a requirement for prolonged surveillance; the lack of a sensitive serum marker (Mason, 1991) for seminoma, making it difficult to monitor patients sufficiently closely to detect small volume relapse; and, finally, the lack of verified prognostic factors for relapse, making it difficult to predict the higher risk patients (Horwich et al., 1992; Von der Maase et al., 1993) . In contrast surveillance is a more attractive option in the management of stage I NSGCT and is the conventional management for patients in the UK (Horwich, 1993; Cullen, 1991) . Clear prognostic factors for relapse exist (Freedman et al., 1987; Read et al., 1992) . Follow-up is easier: sensitive tumour markers are available in over 60% of cases (Mason 1991) . Over 90% of relapses occur within the first year (Freedman et al., 1987; Read et al., 1992) making prolonged intensive follow-up unnecessary.
A substantial minority of patients present with a combination of both seminoma and NSGCT in the postorchidectomy specimen (Horwich, 1991 (Pugh and Cameron, 1976) or combined germ cell tumours. Combined tumours were defined as those containing both teratomatous and seminomatous tumour (Horwich, 1991; Pugh and Cameron, 1976; Ray, 1974) (Figure 1 ). All relevant clinicopathological data were recorded prospectively on a dedicated computer data base. This included the MRC prognostic risk factors for relapse: vascular and lymphatic invasion, lack of yolk sac elements and the presence of undifferentiated elements (Freedman et al., 1987; Read and Stenning, 1992) . In this cohort of patients the incidence and age at presentation of the three histological groups were analysed.
A total of 320 patients with seminoma were treated with adjuvant radiotherapy and 123 patients with NSGCT treated with adjuvant chemotherapy. The remaining 530 patients were managed with surveillance post orchidectomy. A total of 292 (55%) had pure NSGCT, 121 (23%) had combined tumours and 117 (22%) had pure seminoma (Duchesne et al., 1990; Horwich et al., 1992) . The eligibility criteria for patients with seminoma treated with surveillance or adjuvant radiotherapy was identical (Duchesne et al., 1990; Cullen, 1991) . Furthermore, assessment of the MRC histological risk factors showed that tumour characteristics for all patients managed by surveillance were similar to those treated by immediate adjuvant chemotherapy or radiation (Table I ). This shows that there was no selection bias between the three groups and that patients managed by surveillance are representative of the entire patient population.
Statistical considerations
The age at presentation within the three histological groups was analysed by the Mann-Whitney test. The incidence of prognostic factors for relapse and the patterns of disease at relapse were analysed by the chi-square test. The relapse-free survival was measured from the date of orchidectomy and analysed by the log-rank method (Peto et al., 1977) .
Results
Pure seminoma was present in 45% (437 patients (Figure 2 ). There was a statistical age difference between each of these groups (Mann -Whitney P <0.05). Likewise, in the surveillance only patients age at presentation was statistically distinct between the three groups (27 years, 32 years and 37 years respectively). For the groups of patients managed by surveillance, the actuarial 5 year relapse-free survival was 69.5% NSGCT, 71% combined tumours and 84% seminoma (Figure 3 ). There was no statistical difference between the combined tumour and NSGCT groups (P=0.5, log-rank test) but a strong difference with combined tumour vs seminoma (P=0.006) and NSGCT vs seminoma (P=0.005). Analysis of the time distribution of relapse demonstrated similar patterns for NSGCT and combined tumours and both were distinctly different from seminoma (Figure 3 ). For the NSGCT and combined tumour patients who relapsed (or were censored) within 5 years, a significantly greater proportion relapsed from 0-1 years than 1-2 or 2-5 years (NSGCT 81%, 9% and 10%; combined tumours 74%, 12%, 14%). In contrast, for seminoma the relapses were spread evenly over 5 years (0-1 years 38%, 1-2 years 28%, 2-5 years 34%). The anatomical pattern of relapse was also similar for the combined tumour and NSGCT groups (Table  II and Figure 4) 
Discussion
Our study shows that the median age at presentation for patients with stage I testicular germ cell tumour of the three histological subgroups was distinctly different. This agrees with the findings of previous authors (Pugh and Cameron, 1976) . Patients with combined tumours (33 years) were closer in age to those with seminoma (36 years) than those with NSGCT (27 years). The clinical significance of this phenomenon is small as patients in all three groups commonly present at ages between 27 and 36 years (Horwich, 1991) and age is not a prognostic indicator for relapse (Horwich et al., 1992 ; Von der Maase et al., 1993; Freedman et al., 1987; Read et al., 1992 (Horwich, 1993; Duchesne et al., 1990; Horwich et al., 1992) and other institutions (Cullen, 1991; Oliver et al., 1994; Von der Maase et al., 1993; Thomas et al., 1989) . This study was, therefore, necessary to establish which element within combined tumours exerts the strongest influence on clinical outcome. By doing so, the most appropriate management pathway for patients with histologically defined combined tumours could be determined. Our analysis demonstrated that despite these different ages at presentation, patients with combined tumours behaved in a similar manner to those with pure NSGCT: the 5 year relapse-free survival was the same (69.5% and 71%); the time pattern of relapse was the same-most patients relapsed in the first year rather than spread over the first 5 years as in seminoma (Figure 3) , the anatomical pattern of relapse was identical-92% of seminomas occurred within the para-aortic nodes as opposed to 47% NSGCT and 46% combined tumours (Figure 4 ).
This study confirms the clinical impression among experienced clinicians (Horwich, 1993; Cullen, 1991; Hoeltl et al., 1992) . The association of seminoma within a histologically confirmed NSGCT has no influence on the clinical outcome of patients managed with surveillance post orchidectomy. Patients with histologically combined stage I testicular germ cell tumours should be managed with the same intent as those with pure NSGCT.
